| Symbol | BVAXF |
|---|---|
| Name | BIOVAXYS TECHNOLOGY CORP. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | M8W 3C4 Canada ON 146 Thirtieth Street Suite 100 |
| Telephone | +1 740 358 0555 |
| Fax | — |
| — | |
| Website | https://www.biovaxys.com |
| Incorporation | CA |
| Incorporated On | 2018 |
| Employees | — |
| Fiscal Year | 10/31 |
| Public Since | — |
| Exchanges | OTC;OTCQB;NASDAQ |
| Auditor | Dale Matheson Carr-Hilton Labonte LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | 0001882559 |
| Description | BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological diseases. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. Additional info from OTC: Additional info from OTCQB: |
No news found.